Bank of New York Mellon Corp Raises Holdings in Hims & Hers Health, Inc. $HIMS

Bank of New York Mellon Corp lifted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 5.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,325,567 shares of the company’s stock after purchasing an additional 65,275 shares during the quarter. Bank of New York Mellon Corp owned 0.59% of Hims & Hers Health worth $66,080,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Quaker Wealth Management LLC purchased a new position in Hims & Hers Health in the 2nd quarter worth about $29,000. Bessemer Group Inc. grew its stake in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after acquiring an additional 312 shares during the period. Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health during the first quarter valued at approximately $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Hims & Hers Health during the first quarter valued at approximately $41,000. Finally, Larson Financial Group LLC boosted its holdings in Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after purchasing an additional 458 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $41.04 on Monday. The business has a 50-day simple moving average of $51.28 and a two-hundred day simple moving average of $51.17. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. Hims & Hers Health, Inc. has a 52 week low of $19.15 and a 52 week high of $72.98. The stock has a market cap of $9.28 billion, a price-to-earnings ratio of 76.00, a PEG ratio of 8.07 and a beta of 2.20.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. During the same quarter last year, the firm posted $0.32 earnings per share. The company’s revenue was up 49.2% compared to the same quarter last year. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity

In other Hims & Hers Health news, insider Michael Chi sold 900 shares of the firm’s stock in a transaction dated Friday, October 10th. The stock was sold at an average price of $58.25, for a total transaction of $52,425.00. Following the sale, the insider directly owned 291,439 shares of the company’s stock, valued at $16,976,321.75. This trade represents a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 2,637 shares of the business’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $50.10, for a total value of $132,113.70. Following the completion of the transaction, the insider owned 158,493 shares in the company, valued at $7,940,499.30. The trade was a 1.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 709,699 shares of company stock worth $37,499,167 in the last three months. Company insiders own 13.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on HIMS shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Wednesday. Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday. UBS Group set a $32.00 target price on Hims & Hers Health in a research report on Tuesday, November 4th. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a research note on Friday, September 12th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $45.27.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.